NASDAQ:MDRX Veradigm - MDRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veradigm Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $13.05 +0.14 (+1.08%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$12.65▼$13.0550-Day Range$12.89▼$18.4552-Week Range$12.64▼$23.25Volume1.62 million shsAverage Volume1.46 million shsMarket Capitalization$1.43 billionP/E Ratio30.35Dividend YieldN/APrice Target$20.90 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Veradigm MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside60.2% Upside$20.90 Price TargetShort InterestBearish9.04% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.65Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth6.25%From $0.64 to $0.68 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.34 out of 5 starsBusiness Services Sector130th out of 326 stocksComputer Integrated Systems Design Industry12th out of 35 stocks 3.1 Analyst's Opinion Consensus RatingVeradigm has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.90, Veradigm has a forecasted upside of 60.2% from its current price of $13.05.Amount of Analyst CoverageVeradigm has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.04% of the float of Veradigm has been sold short.Short Interest Ratio / Days to CoverVeradigm has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Veradigm has recently decreased by 1.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVeradigm does not currently pay a dividend.Dividend GrowthVeradigm does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeradigm has received a 59.51% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Computerized clinical decision support software", "Personal health record software", and "Documentation software for clinicians" products. See details.Environmental SustainabilityThe Environmental Impact score for Veradigm is -0.62. Previous Next 2.6 News and Social Media Coverage News SentimentVeradigm has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Veradigm this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for MDRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Veradigm to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veradigm insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.29% of the stock of Veradigm is held by insiders.Percentage Held by Institutions99.76% of the stock of Veradigm is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Veradigm are expected to grow by 6.25% in the coming year, from $0.64 to $0.68 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veradigm is 30.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Veradigm is 30.35, which means that it is trading at a less expensive P/E ratio than the Business Services sector average P/E ratio of about 301.85.Price to Earnings Growth RatioVeradigm has a PEG Ratio of 1.19. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVeradigm has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Veradigm (NASDAQ:MDRX) StockVeradigm, Inc. engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segments. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units. The firm solutions include All EMRs, All Population Health Management, Patient Engagement, and Precision Medicine. The company was founded in 1986 and is headquartered in Chicago, IL.Read More Receive MDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter. Email Address MDRX Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comVeradigm (NASDAQ:MDRX) Issues FY23 Earnings GuidanceMarch 24, 2023 | americanbankingnews.comVeradigm (NASDAQ:MDRX) Releases FY 2023 Earnings GuidanceApril 1, 2023 | Vantage Point (Ad)What To Do With Your Trades TodayThere’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts March 23, 2023 | finance.yahoo.comVeradigm Network Solution Practice Fusion EHR Receives Top RankingMarch 22, 2023 | finance.yahoo.comVeradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing, Provides Update on 4th Quarter and Full Fiscal Year 2022 Reporting of ResultsMarch 22, 2023 | americanbankingnews.comVeradigm Inc. (NASDAQ:MDRX) Receives $20.90 Consensus Target Price from BrokeragesMarch 20, 2023 | finance.yahoo.comDespite shrinking by US$50m in the past week, Veradigm (NASDAQ:MDRX) shareholders are still up 139% over 3 yearsMarch 14, 2023 | finance.yahoo.comVeradigm Practice Management Ranks First in Practice Management Solutions from Black Book™ ResearchApril 1, 2023 | Investorplace Media (Ad)5 Hypergrowth Stocks to Buy NowLuke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. March 1, 2023 | businesswire.comThe Law Offices of Frank R. Cruz Continues Investigation of Veradigm Inc. (MDRX) on Behalf of InvestorsMarch 1, 2023 | finance.yahoo.comVeradigm Inc. Update on 4th Quarter and Full Fiscal Year 2022 Reporting of ResultsFebruary 28, 2023 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Veradigm Inc. (MDRX) on Behalf of InvestorsFebruary 22, 2023 | finance.yahoo.comVeradigm Announces Two New Appointments to Its BoardFebruary 21, 2023 | finance.yahoo.comVeradigm to Release Fourth Quarter and Fiscal Year 2022 Financial Results March 1February 13, 2023 | finance.yahoo.comVeradigm and HealthVerity Collaborate to Advance Real-World Evidence and Care for Patients with Cardiovascular Disease and DiabetesFebruary 9, 2023 | finance.yahoo.comVeradigm FollowMyHealth Named Most Improved Software Product by KLASJanuary 30, 2023 | finance.yahoo.comVeradigm® Network EHR Data is Now Available in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) FormatJanuary 30, 2023 | finance.yahoo.comWhat Does Veradigm Inc.'s (NASDAQ:MDRX) Share Price Indicate?January 11, 2023 | finance.yahoo.comVeradigm Takes Action with FY23 Outlook and Major Share Buyback InitiativeJanuary 11, 2023 | finance.yahoo.comVeradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023January 10, 2023 | finance.yahoo.comVeradigm Building Momentum Across All MarketsJanuary 9, 2023 | finance.yahoo.comVeradigm Announces Strategic Investment in HolmuskJanuary 7, 2023 | finance.yahoo.comAn Intrinsic Calculation For Veradigm Inc. (NASDAQ:MDRX) Suggests It's 49% UndervaluedJanuary 6, 2023 | finance.yahoo.comVeradigm to Present at the 2023 J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | finance.yahoo.comAllscripts Announces Corporate Name Change to Veradigm Inc.December 2, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Allscripts (MDRX)November 30, 2022 | finance.yahoo.comSphere's TrustCommerce® Healthcare Payments Platform Now Integrated with Veradigm® Practice ManagementSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter. Email Address MDRX Company Calendar Last Earnings11/04/2021Today4/01/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Computer integrated systems design Sub-IndustryHealth Care Technology SectorBusiness Services Current SymbolNASDAQ:MDRX CUSIP01988P10 CIK1124804 Webwww.allscripts.com Phone(800) 334-8534Fax313-322-9600Employees8,000Year Founded1986Price Target and Rating Average Stock Price Forecast$20.90 High Stock Price Forecast$26.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+60.2%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.43 Trailing P/E Ratio30.35 Forward P/E Ratio20.39 P/E Growth1.19Net Income$134.44 million Net Margins7.25% Pretax Margin14.59% Return on Equity10.74% Return on Assets6.68% Debt Debt-to-Equity Ratio0.17 Current Ratio3.20 Quick Ratio3.20 Sales & Book Value Annual Sales$1.50 billion Price / Sales0.95 Cash Flow$2.77 per share Price / Cash Flow4.71 Book Value$11.49 per share Price / Book1.14Miscellaneous Outstanding Shares109,260,000Free Float106,758,000Market Cap$1.43 billion OptionableOptionable Beta1.01 Social Links Key ExecutivesRichard J. PoultonChief Executive Officer & DirectorThomas LanganPresidentRick DipperChief of Staff & Head-Business OperationsLeah JonesChief Financial & Accounting OfficerJoseph R. RostockChief Technology Officer & SVP-Product EngineeringKey CompetitorsAurora InnovationNASDAQ:AURTDCXNYSE:TDCXSmartRentNYSE:SMRTKyndrylNYSE:KDParsonsNYSE:PSNView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCSold 38,425 shares on 2/28/2023Ownership: 0.345%Macquarie Group Ltd.Sold 52,675 shares on 2/21/2023Ownership: 0.104%Truist Financial CorpBought 39,860 shares on 2/17/2023Ownership: 0.036%State of WyomingBought 9,835 shares on 2/16/2023Ownership: 0.015%Legal & General Group PlcSold 1,188 shares on 2/15/2023Ownership: 0.288%View All Insider TransactionsView All Institutional Transactions MDRX Stock - Frequently Asked Questions Should I buy or sell Veradigm stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares. View MDRX analyst ratings or view top-rated stocks. What is Veradigm's stock price forecast for 2023? 5 Wall Street analysts have issued 1-year price objectives for Veradigm's shares. Their MDRX share price forecasts range from $17.00 to $26.00. On average, they predict the company's stock price to reach $20.90 in the next twelve months. This suggests a possible upside of 60.2% from the stock's current price. View analysts price targets for MDRX or view top-rated stocks among Wall Street analysts. How have MDRX shares performed in 2023? Veradigm's stock was trading at $17.64 at the beginning of the year. Since then, MDRX stock has decreased by 26.0% and is now trading at $13.05. View the best growth stocks for 2023 here. When is Veradigm's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our MDRX earnings forecast. How were Veradigm's earnings last quarter? Veradigm Inc. (NASDAQ:MDRX) released its quarterly earnings results on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The software maker earned $369 million during the quarter, compared to analyst estimates of $376.09 million. Veradigm had a net margin of 7.25% and a trailing twelve-month return on equity of 10.74%. Veradigm's quarterly revenue was down 8.2% on a year-over-year basis. During the same period last year, the company earned $0.15 earnings per share. What ETFs hold Veradigm's stock? ETFs with the largest weight of Veradigm (NASDAQ:MDRX) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Invesco Dynamic Software ETF (PSJ), Harbor Health Care ETF (MEDI), Invesco S&P SmallCap Health Care ETF (PSCH), Fidelity Digital Health ETF (FDHT), Invesco DWA Healthcare Momentum ETF (PTH), Inspire Fidelis Multi Factor ETF (FDLS) and Cambria Shareholder Yield ETF (SYLD). How will Veradigm's stock buyback program work? Veradigm declared that its Board of Directors has authorized a stock repurchase program on Wednesday, May 26th 2021, which authorizes the company to repurchase $350,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 14% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board believes its shares are undervalued. What guidance has Veradigm issued on next quarter's earnings? Veradigm issued an update on its FY 2023 earnings guidance on Wednesday, March, 22nd. The company provided earnings per share (EPS) guidance of $0.80-$0.90 for the period, compared to the consensus EPS estimate of $0.90. The company issued revenue guidance of $615.00 million-$635.00 million, compared to the consensus revenue estimate of $649.05 million. What is Paul Black's approval rating as Veradigm's CEO? 796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees. What other stocks do shareholders of Veradigm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI). What is Veradigm's stock symbol? Veradigm trades on the NASDAQ under the ticker symbol "MDRX." How do I buy shares of Veradigm? Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Veradigm's stock price today? One share of MDRX stock can currently be purchased for approximately $13.05. How much money does Veradigm make? Veradigm (NASDAQ:MDRX) has a market capitalization of $1.43 billion and generates $1.50 billion in revenue each year. The software maker earns $134.44 million in net income (profit) each year or $0.43 on an earnings per share basis. How many employees does Veradigm have? The company employs 8,000 workers across the globe. Does Veradigm have any subsidiaries? The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.Read More How can I contact Veradigm? Veradigm's mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The official website for the company is www.allscripts.com. The software maker can be reached via phone at (800) 334-8534, via email at stephen.shulstein@allscripts.com, or via fax at 313-322-9600. This page (NASDAQ:MDRX) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.